APA (7th ed.) Citation

Gueorguieva, I., Willis, B. A., Chua, L., Chow, K., Ernest, C. S., Shcherbinin, S., . . . Sims, J. R. (2023). Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease. Clinical pharmacology and therapeutics, 113(6), 1258-1267. https://doi.org/10.1002/cpt.2875

Chicago Style (17th ed.) Citation

Gueorguieva, Ivelina, Brian A. Willis, Laiyi Chua, Kay Chow, C. Steven Ernest, Sergey Shcherbinin, Paul Ardayfio, Garrett R. Mullins, and John R. Sims. "Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease." Clinical Pharmacology and Therapeutics 113, no. 6 (2023): 1258-1267. https://doi.org/10.1002/cpt.2875.

MLA (9th ed.) Citation

Gueorguieva, Ivelina, et al. "Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease." Clinical Pharmacology and Therapeutics, vol. 113, no. 6, 2023, pp. 1258-1267, https://doi.org/10.1002/cpt.2875.